Alkermes plc
http://www.alkermes.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Alkermes plc
US FDA's Delay In Acting On Moderna RSV Vaccine Adds To Growing List of User Fee Goal Misses
Administrative constraints adds Moderna’s mRNA-1345 to the recently increasing number of US FDA user fee goal date misses.
Takeda Gets A Try-Before-You-Buy Option In Alzheimer’s Immunotherapy
The Japanese company will await imaging results to see if AC Immune’s candidate ACI-24.060 can help prevent or remove plaques before finalizing the deal.
The Life Of A Blockbuster
The industry’s top-selling drugs generate billions in revenues each year. Scrip analyzed data on nearly 200 blockbuster drugs to see which are forecast to make the most at peak and over a 14-year time horizon.
Chinese Drug Makers Trim, Boost Pipelines In New R&D Drive
The ranks of B7-H3-targeting antibody-drug conjugates under development in China have seen their first dropout, although elsewhere there are two FGFR2b-directed ADCs with first-in-class potential on the horizon. Meanwhile, there have been other discontinuations of KRAS G12C inhibitors and anti-BCMA CAR-T cell therapies in the country, while new players have surfaced in the areas of mRNA cancer vaccines and amyloid-beta-targeting antibodies for Alzheimer’s disease.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Rodin Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice